Making a bigger difference to people with lung disease

Kay Boycott, Chief Executive of the Asthma UK and British Lung Foundation Partnership, explains what’s changing in 2020

From 1 January 2020, Asthma UK and the British Lung Foundation will officially join forces.

The merger allows the two charities to share their combined energy and passion to make an even bigger difference to everyone affected by asthma and other lung diseases.
  
It will see us – as the Asthma UK and British Lung Foundation Partnership – become a stronger, even more powerful voice for change. 

We have already seen how partnership working can lead to real and significant improvements in outcomes for people affected by lung disease.

This move will strengthen and build on previous collaborations such as the Taskforce for Lung Health, BREATHE – the Health Data Research Hub for Respiratory Health and our work campaigning to deliver safer air. 

It also makes sense for us to share running costs and office spaceIt is expected up to £2 million could be released each year to enable more investment in world-leading researchsupport services and campaigning.  

Both AUK and BLF will retain their individual identities and we’ll continue to research asthma and lung diseases, provide information and support, run our expert helplines, and campaign and develop policy.

Your continued support is vital

Lung diseasesuch as asthma have a devastating impact on individuals, their friends and families. And the level of demand on the NHS is growing. That’s why your continued support is vital.
 
You’ll be able to make a difference to the lives of those affected by asthma in the same ways as before. You can still fund Asthma UK’s world-class research and our nurse Helpline.

As a supporter, you’ll continue to hear from Asthma UK regularly with the latest asthma related news, health advice and research, and the different ways you can help support our work.

As a merger of equals, the Partnership will be able to offer more opportunities for supporters to work with us to find new medicines and treatments, to improve NHS services and to protect future generations from lung disease. 

I am very pleased and honoured to have the opportunity to lead the start-up of this new partnership as its first chief executive.